Growth hormone (GH) the most abundant hormone secreted by the anterior pituitary gland could have a role with other growth factors in wound healing because they can help in the physiological wound healing process.Aims: To investigate the effects of GH on facial skin wound healing in rabbits and to evaluate its effect on "insulin-like growth factor (IGF-1)" and "transforming growth factor- β (TGF-β)" in serum. Material and Method: Thirty healthy male rabbits included in this study were classified into two groups according to the day of euthanization 7 and 14 days of study, each group was subdivided into three groups; negative control group, positive control group, and treatment group, full-thickness circle 1 cm wounds were excised in the skin of the forehead for each rabbit without any medication.3-(treated group) full-thickness circle 1 cm wounds will excise in the skin of the forehead for each rabbit, 0.1ml [contain 1.2mg /3.6 IU] of growth hormone injected subcutaneously around the incision, the injection process is every other day.Result: showed a highly significant difference among all study groups in serum TGF-β (ng/L) and IGF (ng/ml) during the first and second weeks. the serum TGF-β at the end of the first and second weeks showed a significant elevation in the treatment group when compared to the other study groups. There is no significant difference between the two control groups. The serum IGF at the end of the first and second weeks showed a significant difference in IGF levels among all study groups.Conclusions: Topical GH has a role in skin wound healing since it can increase the serum level of TGF-β. GH also causes a decrease in serum IGF. Topical GH may have a positive impact on skin wound healing.

• MeSH
• Administration, Topical MeSH
• Animal Experimentation MeSH
• Wound Healing * physiology   drug effects   MeSH
• Injections, Subcutaneous MeSH
• Insulin-Like Growth Factor I analysis   physiology   metabolism   MeSH
• Rabbits MeSH
• Skin injuries   MeSH
• Face MeSH
• Growth Hormone administration & dosage   therapeutic use   MeSH
• Case-Control Studies MeSH
• Transforming Growth Factor beta analysis   physiology   metabolism   MeSH
• Check Tag
• Rabbits MeSH

Endodontic treatment of immature permanent teeth with necrotic pulp poses several clinical challenges and is one of the most demanding interventions in endodontics. Recently, with new discoveries in the field of tissue engineering, novel treatment protocols have been established. The most promising treatment modality is revascularization, whose integral part is the exposure of collagen matrix and embedded growth factors. However, optimization of the treatment protocol requires a development of analytical procedures able to analyze growth factors directly on the sample surface. In this work, method based on surface-enhanced Raman spectroscopy (SERS) was developed to investigate the influence of the time of the medical treatment using EDTA on exposure and accessibility of the growth factors, namely TGF-ß1, BMP-2, and bFGF on the dentine surface. The nanotags, which consist of magnetic Fe3O4@Ag nanocomposite covalently functionalized by tagged antibodies (anti-TGF-ß1-Cy3, anti-BMP-2-Cy5, and anti-bFGF-Cy7), were employed as a SERS substrate. Each antibody was coupled with a unique label allowing us to perform a parallel analysis of all three growth factors within one analytical run. Developed methodology presents an interesting alternative to a fluorescence microscopy and in contrary allows evaluating a chemical composition and thus minimizing possible false-positive results. Graphical abstract.

• MeSH
• Dentin chemistry   MeSH
• Fibroblast Growth Factor 2 analysis   MeSH
• Dental Pulp Cavity chemistry   MeSH
• Bone Morphogenetic Protein 2 analysis   MeSH
• Humans MeSH
• Nanocomposites chemistry   MeSH
• Ferrosoferric Oxide chemistry   MeSH
• Spectrum Analysis, Raman methods   MeSH
• Silver chemistry   MeSH
• Transforming Growth Factor beta analysis   MeSH
• Check Tag
• Humans MeSH
• Publication type
• Journal Article MeSH

Projekt řeší molekulární biologii ovariálních karcinomů ve vztahu k odpovědi na léčbu. 1)Zhodnocení genových polymorfismů ABCB1,ABCC1,GST, proteinů Pgp, MRP1-kódovaných těmito geny, chemorezistence/chemosensitivity in vitro (MTT test) u pacientek diagnostikovaných 2013-2015 a retrospektivně u pacientek s již stanoveným Pgp, MRP1, MTT testem 2006-2009 ve vztahu k PFS a OS. 2) Stanovení genových polymorfismů interleukinu 8, genové exprese endoglinu,FGF,angiopoetinu a proangiogenních faktorů(VEGF,TGF?,TGFß,bFGF) v závislosti na odpovědi a typu primární léčby u pacientek diagnostikovaných 2013-2015 a retrospektivně z ovariální nádorové tkáně zamražené 2006-2009. 3) Zhodnocení kardiotoxicity paklitaxel+karboplatina versus paklitaxel+karboplatina+bevacizumab (EKG,TK,ECHOsrdce,markery kardiotoxicity NTproBNP,cTnT,cTnI,CKMB,MYO,hFABP,GPBB) a její vztah k chemorezistenci a genovým polymorfismům. Projekt umožní molekulárně biologickou predikci odpovědi na léčbu u pacientek s karcinomem ovaria.; This project is intent on assesment of molecular biology markers useful in prediction of therapeutic response in ovarian cancer patients by:1)Determination of ABCB1, ABCC1, GST polymorphisms, resistance proteins Pgp, MRP1, in vitro drug resistance/sensitivity and evaluation of their correlation with medical outcome (PFS, OS, side effects). 2) Assay of polymorphisms of the Interleukin-8 gene, endoglin, FGF, angiopoetin gene expression, pro-angiogenesis markers (VEGF,TGF?,TGFß,bFGF) and their correlation with kind of primary farmacotherapy and medical outcome (PFS, OS).3) Analysis of cardiotoxicity of standard primary chemotherapy (Paclitaxel + Carboplatin) versus primary therapy (Paclitaxel + Carboplatin + Bevacizumab) by ECG, blood pressure, ECHO, markers of cardiotoxicity (NT-proBNP,cTnT,cTnI,CKMB,MYO,h-FABP,GPBB) and their correlation with genetic polymophisms and drug resistance. This project support molecular biology prediction of the therapeutic response in ovarian cancer patients.

• MeSH
• ATP-Binding Cassette Transporters analysis   MeSH
• Survival Analysis MeSH
• Bevacizumab adverse effects   MeSH
• Drug Resistance, Neoplasm MeSH
• Cytotoxicity Tests, Immunologic MeSH
• Echocardiography MeSH
• Enzyme-Linked Immunosorbent Assay methods   utilization   MeSH
• Fibroblast Growth Factor 2 analysis   MeSH
• Glutathione S-Transferase pi analysis   MeSH
• Calgranulin B analysis   MeSH
• Carboplatin adverse effects   MeSH
• Carcinoma drug therapy   MeSH
• Cardiotoxicity MeSH
• Molecular Biology MeSH
• Biomarkers, Tumor MeSH
• Ovarian Neoplasms drug therapy   MeSH
• Drug-Related Side Effects and Adverse Reactions MeSH
• ATP Binding Cassette Transporter, Subfamily B analysis   MeSH
• Paclitaxel adverse effects   MeSH
• Polymerase Chain Reaction methods   utilization   MeSH
• Polymorphism, Genetic MeSH
• Multidrug Resistance-Associated Proteins analysis   MeSH
• Antineoplastic Combined Chemotherapy Protocols MeSH
• Receptors, Vascular Endothelial Growth Factor analysis   MeSH
• Transforming Growth Factor alpha analysis   MeSH
• Transforming Growth Factor beta analysis   MeSH
• Treatment Outcome MeSH
• Women MeSH

• Conspectus
• Patologie. Klinická medicína
• NML Fields
• gynekologie a porodnictví
• onkologie
• biologie
• genetika, lékařská genetika
• NML Publication type
• závěrečné zprávy o řešení grantu IGA MZ ČR

1. Dynamické sledování plasmatických hladin VEGF, TGF a buněčné protinádorové imunity u pacientů s kolorektálním karcinomem v závislosti na klinickém stadiu, odpovědi na léčbu (ORR), období bez progrese onemocnění (PFS), prognoze a stadiu onemocnění. V případě korelace získáme nové biomarkery onemocnění. 2. Vyhodnocení korelace hladin VEGF, TGF-beta a stavu buněčné imunity v závislosti na typu léčby (cílená biologická léčba, chemoterapie) a ověření možné predikce léčebné odpovědi. 3. Ověření možnosti využití vyšetření VEGF, TGF beta, a stavu buněčné imunity k zpřesnění diagnostiky (nové biomarkery), individualizaci léčebného postupu u nemocných s kolorektálním karcinomem. 4. Využití metod chiroptické spektroskopie k monitorování konformačních a stereochemických změn prostorové struktury biomolekul způsobených patologickými procesy, ke kterým může při vzniku kolorektálního karcinomu docházet.; Annotation IIn patients with colon cancer VEGF,TGF and cellular immunity will be detremined at the the entrance into the study and than every 6 months. Spectroscopic analysis of plasma samples using chiroptical methods combined with UV-VIS absorption, fluorescence and Raman spectroscopy will be tested with the aim to develop a new approach for the early stage and non-invasive diagnosis of colon cancer Annotation II We will seek the correlation of the above mentioned parameters with the clinical status,survival time, disease free time and response rate Annotation III Statistic comparision of the parameters according to the type of therapy (with or without monoclonal anti VEGF antibodies etc) Annotation IV Correlation of VEGF, TGF , s and cellular immunity with clinical status and with the response therapy may serve as a new predicitve marker to therapy (with monoclonal antibodies) as well as marker of the disease stage.

• MeSH
• CD3 Complex MeSH
• CD8 Antigens MeSH
• T-Lymphocytes, Cytotoxic MeSH
• Enzyme-Linked Immunosorbent Assay MeSH
• Precision Medicine MeSH
• Biomarkers, Tumor analysis   blood   MeSH
• Colonic Neoplasms immunology   MeSH
• Prognosis MeSH
• Antineoplastic Agents therapeutic use   MeSH
• Transforming Growth Factor beta analysis   blood   MeSH
• Vascular Endothelial Growth Factors analysis   blood   MeSH

• Conspectus
• Patologie. Klinická medicína
• NML Fields
• gastroenterologie
• hematologie a transfuzní lékařství
• biologie
• NML Publication type
• závěrečné zprávy o řešení grantu IGA MZ ČR

Seminal plasma represents a unique environment for maturation, nutrition, and protection of male germ cells from damaging agents. It contains an array of organic as well as inorganic chemicals, encompassing a number of biologically and immunologically active compounds, including hormones. Seminal plasma contains also various pollutants transferred from outer environment known as endocrine disruptors. They interfere with hormones at the receptor level, act as inhibitors of their biosynthesis, and affect hormone regulation. In this minireview, the main groups of hormones detected in seminal plasma are summarized. Seminal gonadal steroids were investigated mostly with aim to use them as biomarkers of impaired spermatogenesis (sperm count, motility, morphology). Concentrations of hormones in the seminal plasma often differ considerably from the blood plasma levels in dependence on their origin. In some instances (dihydrotestosterone, estradiol), their informative value is higher than determination in blood. Out of peptide hormones detected in seminal plasma, peptides of transforming growth factor beta family, especially antimullerian hormone, and oligopeptides related to thyrotropin releasing hormone have the high informative value, while assessment of seminal gonadotropins and prolactin does not bring advantage over determination in blood. Though there is a large body of information about the endocrine disruptors’ impact on male reproduction, especially with their potential role in decline of male reproductive functions within the last decades, there are only scarce reports on their presence in seminal plasma. Herein, the main groups of endocrine disruptors found in seminal plasma are reviewed, and the use of their determination for investigation of fertility disorders is discussed.

• MeSH
• Endocrine Disruptors * analysis   pharmacology   metabolism   MeSH
• Fertility drug effects   MeSH
• Hormones * analysis   metabolism   MeSH
• Humans MeSH
• Somatomedins analysis   metabolism   MeSH
• Semen * chemistry   metabolism   MeSH
• Transforming Growth Factor beta analysis   metabolism   MeSH
• Check Tag
• Humans MeSH
• Male MeSH
• Female MeSH
• Publication type
• Research Support, Non-U.S. Gov't MeSH
• Review MeSH

U pacientek s rizikovými faktory i s karcinomem prsu splňujícím vstupní kriteria bude stanovena hladina TGF-beta a vyšetřen stav buněčné imunity v době určení diagnózy. Bude zkoumána korelace hladin TGF-beta a stavu buněčné imunity s klinickým stavem pacientek. Tato vyšetření budou provedena opakovaně v přesně stanovených časových odstupech od vstupu do výzkumného projektu, tj. za 1, 3 a 6 měsíců. Statistické srovnání TGF-beta a ost. imunolog. parametrů u skupin pac. rozdělených dle vel. prim. TU, pozit. či negat. region. LU, výskytu relapsu onemocnění. U jednotlivých pacientek korelace hladin TGF-beta a buněčné imunity s klinickým stavem. Doporučení ke zpřesnění diagnostiky, disp. péče a chemoprevence u pac. s rizik. faktory rozvoje CA prsu. U pac.s CA prsu a pozit.region. LU návrh adekvátní TH. Hodnocení přežití dle sledovaných parametrů, zvážení doporučení imunoterapie.; In pacients with risk factors for developing breast cancer as well as in breast cancer patients fullfilling the criteria of the study , TGF-beta plasma level as well as cellular immunity will be investigated at the time of diagnosis. TGF-beta plasma level as well as cellular immunity in correlation to clinical outcome of patients will be investigated. Those investigations will be repeated in exact time intervals - after 1, 3 and 6 months. Statistical compation TGF-beta and other imunol. paramtrs in groups of pats designed by size of the prime TU, posit./negat. of reg. LN, relaps of the disease. Correlation of TGF-beta levels as well as cell. immunity paramtrs to the clinical outcome. Recommendations to diagnostics, dispensary care and chemoprevention in pats with high risk factors.In pats with breast ca and posit.LN suggestion of accurate therapy. Correlation of survival rate with markers. Supporting immunotherapy sudgestion.

• MeSH
• Immunity, Cellular MeSH
• Immunotherapy MeSH
• Lymph Nodes immunology   MeSH
• Biomarkers, Tumor analysis   MeSH
• Breast Neoplasms diagnosis   prevention & control   MeSH
• Risk Factors MeSH
• Transforming Growth Factor beta analysis   MeSH

• Conspectus
• Patologie. Klinická medicína
• NML Fields
• onkologie
• gynekologie a porodnictví
• hematologie a transfuzní lékařství
• alergologie a imunologie
• NML Publication type
• závěrečné zprávy o řešení grantu IGA MZ ČR

Between 2001 and 2002, 29 patients with advanced inoperable squamous head and neck cancer treated with radiotherapy with or without simultaneous chemotherapy were evaluated for their plasma TGF-beta1 levels prior to the treatment, in the middle of the radiotherapy course and at the end of the treatment. Patients were assessed for treatment response and late morbidity. Predictive value of TGF-beta1 level on either of the assessed parameters was tested. From 29 eligible patients (pts), 18 achieved complete response, 8 partial response and three pts progressed primarily. After a median follow-up of 16 months we recorded 16 cases of grade >1 late morbidity. We found that post-treatment elevated plasma TGF-beta1 level predicts late morbidity grade >1 (p=0.05) rather than pre-treatment level (p=0.062). Neither pre-treatment nor post-treatment plasma TGF-beta1 level has a predictive value to the treatment response (CR vs. no CR, p=0.125 and 0.252, respectively). The post-treatment plasma TGF-beta 1 level can predict late morbidity grade >1 in advanced head and neck cancer treated with radio(chemo)therapy. This could make a basis for dose escalation in selected patients.

• MeSH
• Adult MeSH
• Combined Modality Therapy MeSH
• Middle Aged MeSH
• Humans MeSH
• Head and Neck Neoplasms blood   pathology   therapy   MeSH
• Predictive Value of Tests MeSH
• Prognosis MeSH
• Antineoplastic Agents therapeutic use   MeSH
• Radiotherapy MeSH
• Aged MeSH
• Neoplasms, Squamous Cell blood   pathology   therapy   MeSH
• Transforming Growth Factor beta analysis   MeSH
• Transforming Growth Factor beta1 MeSH
• Tumor Burden MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Male MeSH
• Aged MeSH
• Female MeSH

HGF (Hepatocyte Growth Factor) a TGFβ1 (Transforming Growth Factor β1) jsou cytokiny, které se uplatňují při vzniku a růstu nádorů příštítných tělísek a štítné žlázy. Rozhodli jsme se zjistit, jaké existují změny a závislosti v produkci těchto cytokinů nádorovými buňkami příštítných tělísek ve srovnání s nádory štítné žlázy. Vyšetřovali jsme metodou ELISA koncentrace HGF a TGFβ1 v séru z periferní krve u 28 pacientů s nádorem štítné žlázy (14krát adenom, 14krát papilární karcinom) a u 16 pacientů s adenomem příštítného tělíska a osm pacientů s hyperplázií příštítného tělíska. Výsledky jsme porovnali se sérovými hladinami u zdravých osob. Sérové hladiny HGF u pacientů s parathyroidálním adenomem a hyperplázií jsou významně vyšší ve srovnání se zdravou populací (adenom 1551 ± 592; hyperplázie 2718 ± 1383; zdraví 652 ± 145 pg/ml). Zjistili jsme významně vyšší sérové koncentrace HGF u pacientů s adenomem a a papilárním karcinomem štítné žlázy ve srovnání se zdravou populací (adenom 1496 ± 810; karcinom 1137 ± 862; zdraví 361 ± 83 pg/ml). Předoperační sérové hladiny TGFβ1 vykazují statisticky významné zvýšení u adenomu příštítného tělíska oproti zdravé populaci (adenom 29,74 ± 12,74; hyperplázie 14,81 ± 4,98; zdraví 13,64 ± 5,83 pg/ml). Stejně tak je zajímavý vzestup pooperačních sérových koncentrací TGFβ1 u parathyroidální hyperplázie (28,82 ± 11,84; zdraví 13,64 ± 5,83 pg/ml), kde však nebyla prokázána statistická významnost. Sérové koncentrace TGFβ1 u nodosní strumy a papilárního karcinomu štítné žlázy nevykazovaly statisticky významné rozdíly (adenom 35,87 ± 10,87; karcinom 37,73 ± 12,99; zdraví 28,98 ± 20,02 pg/ml). Změny v produkci růstových faktorů nádorovými buňkami příštítných tělísek a štítné žlázy se odrážejí v jejich koncentracích v periferní krvi. Zvýšení sérových hladin HGF u pacientů s adenomem či hyperplázií příštítných tělísek a u nádorů štítné žlázy lze vysvětlit jejich velmi silnou produkci nádorovými buňkami. Proti tomuto faktu však stojí skutečnost, že po provedené operaci u příštítných tělísek nedošlo k poklesu sérových koncentrací HGF. Tyto výsledky svědčí pro možnost extratumorózní produkce tohoto cytokinu.

HGF (Hepatocyte Growth Factor) and TGFβ1 (Transforming Growth Factor β1) are cytokines that are involved in the formation and growth parathyroid and thyroid tumors. We tried to determine, whether there are changes and relationships in the production of these cytokines by tumor cells of the parathyroid as compared to the thyroid tumors.We determined concentrations of HGF and TGFβ1 in sera from peripheral blood of 28 patients with thyroid cancer (14 adenomas, 14 papillary carcinomas) and of 16 patients with parathyroid adenoma and of 8 patients with parathyroid hyperplasia. The results were compared with the sera levels of healthy people. The levels of HGF in the sera of patients with parathyroid adenoma and hyperplasia are significantly higher as compared to healthy controls (adenoma 1551 ± 592, hyperplasia 2718 ± 1383, controls 652 ± 154 pg/mL).We found significantly higher concentrations of HGF in the sera of patients with thyroid adenoma and papillary carcinoma as compared to healthy controls (adenoma 29.74 ± 12.74, hyperplasia 14.81 ± 4.98, controls 13.64 ± 5.83 pg/mL). Also the increase in the post-surgery levels of TGFβ1 in parathyroid hyperplasia (28.82 ± 11.84, controls 13.64 ± 5.83 pg/mL), although of no statistical significance, seems to be interesting. The concentrations of TGFβ1 in the sera of patients with thyroid nodal goiter and papillary carcinoma did not show any significant differences (adenoma 35.87 ± 10.87, carcinoma 37.73 ± 12.99, controls 28.98 ± 20.02 pg/mL). The changes in the growth factor production by parathyroid and thyroid tumor cells are reflected by their concentrations in peripheral blood. The elevation of HGF sera levels in patients with parathyroid adenoma or hyperplasia and in thyroid tumors can be explained by very high production of HGF by tumor cells. Contradictory to that is the fact, that after the parathyroid surgery no decrease of HGF in sera was observed. These results are in favor of an extra-tumor production of this cytokine.

• MeSH
• Research Support as Topic MeSH
• Hepatocyte Growth Factor analysis   blood   MeSH
• Humans MeSH
• Parathyroid Neoplasms blood   MeSH
• Thyroid Neoplasms blood   MeSH
• Transforming Growth Factor beta analysis   blood   MeSH
• Check Tag
• Humans MeSH

• MeSH
• Cytokines analysis   physiology   MeSH
• Research Support as Topic MeSH
• Interleukin-1 analysis   physiology   MeSH
• Interleukins analysis   physiology   MeSH
• Humans MeSH
• Myocardial Reperfusion Injury physiopathology   MeSH
• Transforming Growth Factor beta analysis   physiology   MeSH
• Tumor Necrosis Factors analysis   physiology   MeSH
• Check Tag
• Humans MeSH

• MeSH
• Biopsy MeSH
• Cyclosporine administration & dosage   MeSH
• Adult MeSH
• Research Support as Topic MeSH
• Transplantation, Homologous MeSH
• Immunohistochemistry MeSH
• Immunosuppressive Agents administration & dosage   MeSH
• Kidney chemistry   pathology   MeSH
• Middle Aged MeSH
• Humans MeSH
• Aged MeSH
• Tacrolimus administration & dosage   MeSH
• Transforming Growth Factor beta analysis   MeSH
• Kidney Transplantation MeSH
• Check Tag
• Adult MeSH
• Middle Aged MeSH
• Humans MeSH
• Aged MeSH
• Female MeSH